• Eighty-nine children with localized rhabdomyosarcoma of orofacial and laryngopharyngeal sites were treated in accordance with the first and second Intergroup Rhabdomyosarcoma Study (IRS) protocols (IRS-I and IRS-II) between 1972 and 1984. Treatment included surgery (or biopsy) and chemotherapy for all patients and radiotherapy in the majority. The actuarial estimate of the three-year survival rate for all patients was 83% and did not differ significantly by primary site, histologic findings, or presence of adenopathy. A trend for a worse survival rate was seen in clinical group III patients and in those less than 5 years of age at diagnosis. Factors associated with an increased risk of local/regional relapse included omission of radiotherapy and a radiation dose of less than 40 Gy (4000 rad). We conclude that treatment of these patients as recommended in the IRS-I and IRS-II protocols results in very good local and regional tumor control and survival rates. Salvage therapy for local/regional recurrence may yield long-term remission and possibly cure.
(Arch Otolaryngol Head Neck Surg 1987;113:1225-1227)
Wharam MD, Beltangady MS, Heyn RM, Lawrence W, Raney RB, Ruymann FB, Soule EH, Tefft M, Maurer HM. Pediatric Orofacial and Laryngopharyngeal RhabdomyosarcomaAn Intergroup Rhabdomyosarcoma Study Report. Arch Otolaryngol Head Neck Surg. 1987;113(11):1225–1227. doi:10.1001/archotol.1987.01860110091014